Calquence vs Repatha
Side-by-side drug price comparison from Medicare Part D data
Verdict
Repatha costs 93% less per claim than Calquence ($757.00 vs $10105.00). Calquence has a generic alternative available. Total Medicare spending: Calquence at $2.9B vs Repatha at $2.6B.
| Metric | Calquence | Repatha |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $10,105 | $757* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $2.9B | $2.6B |
| Total Claims | 286,000 | 3,420,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 34.2% | 24.6%* |
| Generic Available | Yes | No |
| Condition | Cancer | High Cholesterol |
| Total Beneficiaries | 28,000 | 398,000 |
Repatha costs 93% less per claim than Calquence ($757.00 vs $10105.00). Calquence has a generic alternative available. Total Medicare spending: Calquence at $2.9B vs Repatha at $2.6B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Calquence and Repatha. What follows is the interpretation — which specific axes carry the most weight for Calquence versus Repatha, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.